Medco Taps MolecularMD to Provide BCR-ABL Testing for TKI Inhibitors in CML Patients

Medco will offer MolecularMD's qRT-PCR BCR-ABL test to patients diagnosed with chronic myeloid leukemia in order to monitor their response to tyrosine kinase inhibitors such as Gleevec, Sprycel, and Tasigna.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.